deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02762370

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

A Double-Blind, Randomized, Parallel Group Comparison of the Effects of FX006 and TCA IR (Triamcinolone Acetonide Suspension) on Blood Glucose in Patients With Osteoarthritis of the Knee and Type 2 Diabetes Mellitus

Sponsor: Pacira Pharmaceuticals, Inc

Conditions Osteoarthritis of the Knee Type 2 Diabetes Mellitus
Interventions FX006 32 mg TCA IR 40 mg
Updated 11 times since 2017 Last updated: Jan 22, 2024 Started: Apr 30, 2016 Primary completion: Oct 31, 2016 Completion: Nov 30, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Osteoarthritis of the Knee and Type 2 Diabetes Mellitus and is currently completed. Pacira Pharmaceuticals, Inc leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshotCompleted~Aug 2017 – ~Feb 2018 · 6 months · monthly snapshotCompleted~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Feb 2024 · 26 months · monthly snapshotCompleted~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2021 — Feb 2024 [monthly]

    Completed PHASE2

▶ Show 6 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  3. Feb 2018 — Jun 2018 [monthly]

    Completed PHASE2

  4. Aug 2017 — Feb 2018 [monthly]

    Completed PHASE2

  5. Feb 2017 — Aug 2017 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  6. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pacira Pharmaceuticals, Inc
Data source: Pacira Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations